The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts
- 31 May 2009
- journal article
- Published by Elsevier BV in Bone
- Vol. 44 (5), 908-916
- https://doi.org/10.1016/j.bone.2009.01.010
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent mannerBlood, 2006
- Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approachBritish Journal of Cancer, 2006
- Transformation of Human and Murine Fibroblasts without Viral OncoproteinsMolecular and Cellular Biology, 2005
- Bone Marrow Mesenchymal Stem Cells Provide an Alternate Pathway of Osteoclast Activation and Bone Destruction by Cancer CellsCancer Research, 2005
- Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer ModelClinical Cancer Research, 2004
- Bisphosphonates: new therapeutic agents for the treatment of bone tumorsTrends in Molecular Medicine, 2004
- Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human OsteoblastsBiochemical and Biophysical Research Communications, 2002
- Nitrogen-Containing Bisphosphonates Inhibit Isopentenyl Pyrophosphate Isomerase/Farnesyl Pyrophosphate Synthase Activity with Relative Potencies Corresponding to Their Antiresorptive Potenciesin Vitroandin VivoBiochemical and Biophysical Research Communications, 1999
- Osteoclasts are required for bone tumors to grow and destroy boneJournal of Orthopaedic Research, 1998
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987